Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bacterial Vaginosis Clear all

Conditions: Vaginosis, Bacterial
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more

Conditions: Bacterial Vaginosis, Preterm Delivery
Interventions: Additional vaginal swabs; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Bacterial Vaginosis (BV)
Interventions: LUXSOL copper containing cream, Metronidazole gel; Drug
Lead sponsor: CDA Research Group, Inc.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: VT-1161, Placebo; Drug
Lead sponsor: Viamet; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more

Conditions: Bacterial Vaginosis
Interventions: LACTIN-V, Placebo control substance; Drug
Lead sponsor: Osel, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Bacterial Vaginosis
Interventions: Vaginal microbiome transplant, Oral Metronidazole, Sterile saline; Biological · Drug · Other
Lead sponsor: Douglas Kwon; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Vulvovaginal Candidiasis
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 20 more

Conditions: Vaginal Health
Interventions: Once Daily Women's Probiotic, Placebo; Dietary Supplement · Other
Lead sponsor: Garden of Life, LLC; Industry
Eligibility: 19 Years to 70 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Wellington, Florida

Conditions: Vaginosis, Bacterial
Interventions: Metronidazole Gel; Drug
Lead sponsor: Insud Pharma; Industry
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Long Beach, California • Paramount, California • Bardstown, Kentucky + 5 more

Conditions: Vaginosis, Bacterial, Vaginal Infection
Interventions: GW05, Metronidazole; Drug
Lead sponsor: Graceway Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 20
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • San Diego, California + 16 more

Conditions: Vulvovaginal Candidiasis
Interventions: MGCD290; Drug
Lead sponsor: MethylGene Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 19
States / cities: Birmingham, Alabama • San Diego, California • Lake Worth, Florida + 16 more

Conditions: Bacterial Vaginosis
Interventions: 750 mg metronidazole/ 200 mg miconazole vaginal suppository, Standard of care; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Bacterial Vaginosis, Candida Vaginitis
Interventions: cobas® BV/CV test, BD Max™ Vaginal Panel, Cepheid Xpert Xpress MVP, Hologic Aptima BV Assay; Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 738 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Lakewood, Colorado + 5 more

Conditions: Bacterial Vaginosis
Interventions: NuvaRing; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bacterial Vaginoses
Interventions: Metronidazole, Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Bacterial Vaginosis
Interventions: 5% Monolaurin Vaginal Gel, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Iowa City, Iowa • Durham, North Carolina • Cincinnati, Ohio

Conditions: Candidiasis, Vulvovaginal
Interventions: VT-1161, Fluconazole; Drug
Lead sponsor: Viamet; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Lake Worth, Florida • North Miami, Florida • Brooklyn, New York + 5 more

Conditions: Recurrent Bacterial Vaginosis
Interventions: Secnidazole 2 GM Oral Granules; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Bacterial Vaginosis
Interventions: Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components); Device
Lead sponsor: Vaginal Biome Science; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rosemont, Pennsylvania

Conditions: Bacterial Vaginosis, Vulvovaginal Candidiasis, Trichomoniasis
Interventions: NAAT testing; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bacterial Vaginosis
Interventions: LC106; Drug
Lead sponsor: Caroline Mitchell; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions: CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 19 more

Conditions: Candida Vulvovaginitis
Interventions: Ibrexafungerp, Placebo; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more

Search by objective public record fields.

Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Serial Screening and Treatment of Bacterial Vaginosis Trial

LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis

Vaginal Microbiota Transplant

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Garden of Life Once Daily Women's Probiotic: Vaginal pH and Quality of Life Study

Safety and Tolerability of Metronidazole Gel 1.3%

Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis

Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

A Randomized Controlled Trial of Treatment of Bacterial Vaginosis

Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

Flourish HEC to Prevent Recurrence of BV

Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis

Impact of Clinician-administered Vaginal Live Biotherapeutic Product

RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)